Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an investigational medicine being developed by Abbisko Therapeutics Co., Ltd., met its primary endpoint, demonstrating significant i…
– 출처 : https://www.newswire.co.kr/newsRead.php?no=1000594&sourceType=rss